Drug Profile


Alternative Names: 851A; 851B; epetirimod esylate; R851; S-30563; S-30563-35-65; TAK-851

Latest Information Update: 10 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator 3M Pharmaceuticals
  • Developer Takeda
  • Class Antineoplastics; Antivirals
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Cervical dysplasia; Human papillomavirus infections

Most Recent Events

  • 19 Nov 2013 Profile reviewed - prompted by Wendy's request (via Indu) re CTP18853. Matched R-851 with Epetirimod and requested changes in Thes; only two terminated trials on CT.gov, Takeda's pipeline of October 31, 2013 (TAK-851 no listed); added gel formulation
  • 01 Feb 2009 Discontinued - Phase-II for Cervical dysplasia in Canada (Topical)
  • 01 Feb 2009 Discontinued - Phase-II for Cervical dysplasia in European Union (Topical)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top